The US Food and Drug Administration recently announced the approval of dupilumab, a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways while not suppressing the immune system. It’s the first and only treatment indicated for adults with prurigo nodularis (PN). It has been indicated for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis.
Read the full announcement on the Dermatology Learning Network Here >